BioCentury | Aug 8, 2013
Distillery Therapeutics

Indication: Neurology

...acidic stimulus compared with vehicle. Next steps include optimizing the peptide to improve its potency. Theralpha S.A.S....
BioCentury | Dec 24, 2012
Emerging Company Profile

Aros: Easing IBS pain

...modifying other symptoms. According to Blou, competitors developing therapeutics specifically for IBS pain include Theralpha S.A.S. Theralpha...
...Pharmaceuticals Inc. (NASDAQ:LXRX), The Woodlands, Texas Ono Pharmaceutical Co. Ltd. (Tokyo:4528; Osaka: 4528), Osaka, Japan Theralpha S.A.S....
BioCentury | Oct 18, 2012
Distillery Therapeutics

Indication: Neurology

...respiratory distress. Next steps include characterization of mambalgin peptides in other mouse models of pain. Theralpha S.A.S.'s...
...away pain, page 5). SciBX 5(41); doi:10.1038/scibx.2012.1091 Published online Oct. 18, 2012 Patented; licensed to Theralpha...
BioCentury | Oct 18, 2012
Targets & Mechanisms

Black mamba takes away pain

...inhibit a class of acid-sensing ion channels on the surface of neurons, are licensed to Theralpha S.A.S....
...patent covering the use of mambalgins for pain. The university has licensed the patent to Theralpha...
...in preclinical pharmacokinetic and toxicology studies. The company could not be reached for comment. Theralpha...
BioCentury | Sep 12, 2011
Company News

Theralpha SAS neurology news

...received €2.6 million ($3.6 million) to fund three years of preclinical and clinical development of Theralpha's...
...derivative of the King Cobra neurotoxin hannalgesin is in preclinical development to treat acute pain. Theralpha...
...the Institute of Molecular and Cellular Pharmacology and the Clermont Ferrand Center of Clinical Investigation. Theralpha...
BioCentury | May 16, 2011
Company News

Flamel, Theralpha deal

...The companies partnered to co-develop a controlled-release formulation of Theralpha's THA902 to treat pain. Flamel will...
...THA902 to treat pain. Flamel will contribute its Medusa nanogel polymer drug delivery technology, while Theralpha...
...to treat inflammatory pain. Further terms were not disclosed. Flamel Technologies S.A. (NASDAQ:FLML), Lyon, France Theralpha S.A.S....
Items per page:
1 - 6 of 6
BioCentury | Aug 8, 2013
Distillery Therapeutics

Indication: Neurology

...acidic stimulus compared with vehicle. Next steps include optimizing the peptide to improve its potency. Theralpha S.A.S....
BioCentury | Dec 24, 2012
Emerging Company Profile

Aros: Easing IBS pain

...modifying other symptoms. According to Blou, competitors developing therapeutics specifically for IBS pain include Theralpha S.A.S. Theralpha...
...Pharmaceuticals Inc. (NASDAQ:LXRX), The Woodlands, Texas Ono Pharmaceutical Co. Ltd. (Tokyo:4528; Osaka: 4528), Osaka, Japan Theralpha S.A.S....
BioCentury | Oct 18, 2012
Distillery Therapeutics

Indication: Neurology

...respiratory distress. Next steps include characterization of mambalgin peptides in other mouse models of pain. Theralpha S.A.S.'s...
...away pain, page 5). SciBX 5(41); doi:10.1038/scibx.2012.1091 Published online Oct. 18, 2012 Patented; licensed to Theralpha...
BioCentury | Oct 18, 2012
Targets & Mechanisms

Black mamba takes away pain

...inhibit a class of acid-sensing ion channels on the surface of neurons, are licensed to Theralpha S.A.S....
...patent covering the use of mambalgins for pain. The university has licensed the patent to Theralpha...
...in preclinical pharmacokinetic and toxicology studies. The company could not be reached for comment. Theralpha...
BioCentury | Sep 12, 2011
Company News

Theralpha SAS neurology news

...received €2.6 million ($3.6 million) to fund three years of preclinical and clinical development of Theralpha's...
...derivative of the King Cobra neurotoxin hannalgesin is in preclinical development to treat acute pain. Theralpha...
...the Institute of Molecular and Cellular Pharmacology and the Clermont Ferrand Center of Clinical Investigation. Theralpha...
BioCentury | May 16, 2011
Company News

Flamel, Theralpha deal

...The companies partnered to co-develop a controlled-release formulation of Theralpha's THA902 to treat pain. Flamel will...
...THA902 to treat pain. Flamel will contribute its Medusa nanogel polymer drug delivery technology, while Theralpha...
...to treat inflammatory pain. Further terms were not disclosed. Flamel Technologies S.A. (NASDAQ:FLML), Lyon, France Theralpha S.A.S....
Items per page:
1 - 6 of 6